{"prompt": "['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 8 of 92', 'CR845-CLIN3102', 'measured by the patient-daily reported 24-hour Worst Itching Intensity', 'NRS, and to establish a baseline itch intensity. Patients must not be', 'informed that they need to report a weekly average worst itch score', '>4 to be enrolled in the study. During the first visit of the Run-in', 'Period, patients will be trained on completion of the 24-hour Worst', 'Itching Intensity numerical rating scale (NRS) and will start the', 'reporting of their Worst Itching Intensity NRS daily score. For', 'consistency, patients will be requested to complete the NRS', 'worksheets (either at home or in the dialysis unit, as required) each day', 'at a similar time of day around the normal start time of their dialysis.', 'Patients will be trained on other itch-related patient-reported outcome', '(PRO) worksheets during the Run-in Period or on Day 1 of the', 'Double-blind Treatment Period.', 'If patients continue to meet all inclusion and no exclusion criteria at the', 'end of the 7-day Run-in Period, they will be randomized into the', 'Double-blind Treatment Period in a 1:1 ratio to receive either IV', 'CR845 0.5 mcg/kg or placebo. Patients will be stratified according to', 'their use or non-use of concomitant medications to treat their itch', 'during the week prior to randomization (Run-in Period) as well as the', 'presence or absence of specific medical conditions. These specific', 'medical conditions include:', 'History of fall or fracture (related to fall)', 'Confusional state or mental status change or altered mental', 'status or disorientation', 'Gait disturbance or movement disorder', 'Day 1 of the Double-blind Treatment Period will be defined as the day', 'of administration of the first dose of study drug and will occur on the', 'first dialysis session of the first treatment week (ie, Monday for', 'patients on a Monday-Wednesday-Friday dialysis schedule, or Tuesday', 'for patients on a Tuesday-Thursday-Saturday dialysis schedule).', 'Patients will be administered CR845 or matched placebo as an IV', 'bolus after the end of each dialysis session during the 12-week', 'Double-blind Treatment Period. Each patient is to receive CR845 or', 'placebo 3 times weekly for a total of up to 36 doses.', 'During the Double-blind Treatment Period, patients will continue to', 'report their daily Worst Itching Intensity NRS score over the previous', '24 hours. In addition, during selected study visits (Day 1 and first day', 'of Weeks 5, 9, 11, and 13; ie Days 29, 57, 71, and 85), they will', 'complete other PRO measures (Skindex-10 Scale, 5-D Itch Scale, and', 'Patient Global Impression of Change). Patients will be instructed to', 'record patient-reported outcome measurements at a similar time of day,', 'whether in the dialysis unit (on dialysis days) or at home', '(on non-dialysis days).', 'Blood samples for clinical laboratory tests will be collected at the', 'Screening Visit, Days 1 and 85. Blood samples for biomarkers will be', 'collected at Days 1 and 85. Electrocardiograms (ECGs) will be', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 10 of 95']['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 9 of 92', 'CR845-CLIN3102', 'monitored at the Screening Visit and Day 85. Vital signs will be', 'monitored periodically, and adverse events and concomitant', 'medications will be continuously recorded starting at the Screening', 'Visit until the end of the Discontinuation Period or Early Termination', 'Visit. Use of antipruritic medications, iron, and', 'erythropoiesis-stimulating agents (ESAs) and missed dialysis will be', 'recorded throughout the Double-blind Phase.', 'The Double-blind Treatment Period will be followed by a 2-week', 'Discontinuation Period, during which no study drug will be', 'administered. Patients will be monitored and evaluated for potential', 'physical dependence by completing a Short Opiate Withdrawal Scale', '(ShOWS) daily on dialysis days and on non-dialysis days. Objective', 'Opiate Withdrawal Scale (OOWS) score, adverse events, concomitant', 'medication, body temperature, and vital signs measurements will also', 'be collected at each dialysis visit. During this period, patients will', 'continue to report their NRS scores but only on the dialysis visit.', 'A Structured Safety Evaluation will be performed once during the', 'Run-in Period and weekly (preferably on Wednesday/Thursday) during', 'the Double-blind Treatment Period and Discontinuation Period. The', 'Structured Safety Evaluation is performed by study staff using a list of', 'specific signs/symptoms (eg, mental status change, falls, gait', 'disturbance).', 'Open-label Extension Phase', 'Patients who received at least 30 doses of study drug (either active or', 'placebo) during the 12-week Double-blind Treatment Period and', 'continue to meet other eligibility criteria will have the option to receive', 'open-label CR845 for an additional 52 weeks. The Open-label', 'Extension Phase will be comprised of the Open-label Treatment Period', 'and the Follow-up Period.', 'Each patient will receive CR845 at a dose of 0.5 mcg/kg after each', 'dialysis session, 3 times per week for up to 52 weeks, regardless of', 'whether they had been previously administered placebo or CR845.', 'Prescription dry weight will be recorded every 12 weeks; if there is a', '>10% change from the previous recorded dry weight, then the CR845', 'dose will be adjusted.', 'The first visit and first dosing for the Open-label Extension Phase of', 'the study will occur during the week (+1-week window) following the', 'Discontinuation Period.', 'Patients will complete the 5-D Itch Scale during Weeks 4, 8, 12, 24,', '36, and 52 (preferably at the end of the specified weeks).', 'Clinical laboratory tests, vital signs, adverse events, and concomitant', 'medications will be monitored throughout the Open-label Treatment', 'Period. Blood samples for inflammatory biomarkers will be collected', 'periodically until the Open-label End-of-Treatment or Early', 'Termination Visit. ECGs will be monitored at the Open-label', 'End-of-Treatment or Early Termination Visit.', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 11 of 95']\n\n###\n\n", "completion": "END"}